Test Price
2,800 AED✅ Home Collection Available
TNNI3 Gene (Familial Restrictive Cardiomyopathy Type 1) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-accredited processing using validated Next-Generation Sequencing with MLPA cross-validation.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- ✓ Clinical Guidance: Telephonic post-test genetic counselling with a DHA-licensed Consultant Medical Geneticist to interpret results.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced molecular diagnostic test employs full-gene Next-Generation Sequencing (NGS) to analyze the TNNI3 gene, identifying pathogenic variants responsible for autosomal dominant familial restrictive cardiomyopathy type 1. Achieving a definitive molecular diagnosis enables early cardiac surveillance, cascade family screening, and personalized risk-stratified management plans. Our methodology includes deep intronic coverage for Variants of Uncertain Significance (VUS) and Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large deletions or duplications not captured by standard sequencing.
| Feature | Our Test | Typical Cardiogenetic Panel |
|---|---|---|
| Precision | 99.9% Analytic Sensitivity & Specificity | ~95–98% depending on panel breadth |
| Method | Full-Gene NGS with deep intronic VUS coverage + MLPA backup | Exon-only panels, often missing deep intronic variants |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks |
| Price | 2,800 AED (inclusive of home collection & counselling) | 2,800 – 3,500 AED (often add-ons) |
Physician Insight & Safety Protocols
"A definitive molecular diagnosis through TNNI3 gene sequencing is the cornerstone of preventive cardiology for families with restrictive cardiomyopathy. This test empowers clinicians to implement early echocardiographic surveillance, differentiate phenocopies, and initiate cascade testing for at-risk relatives before clinical onset. The results must be interpreted in the full context of the patient's clinical presentation and family pedigree."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
⚠️ Advisory Notice: Do not discontinue, alter, or initiate any prescribed cardiac medication without consulting your treating physician. This test is a diagnostic aid and does not replace clinical evaluation.
Exclusion Criteria & Emergency Red Flags
- Persons unable to provide informed consent (minors must have legal guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Individuals who have not completed a mandatory pre-test genetic counselling session.
- Unstable acute cardiac condition requiring immediate intervention – this test is strictly for diagnostic and risk-stratification purposes, not for emergency use.
- Seek Immediate Emergency Care if you experience: crushing chest pain, syncope, new-onset palpitations, or sudden shortness of breath.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of this TNNI3 genetic test?
This test identifies pathogenic TNNI3 mutations causing familial restrictive cardiomyopathy, enabling early cardiac surveillance and preventive measures for confirmed carriers. It clarifies the autosomal dominant inheritance risk for biological relatives, guiding personalized cardiology follow-up and pre-symptomatic intervention strategies.
2. How is the sample collected for this genetic test?
A standard peripheral whole blood sample or a single drop of blood on an FTA card is collected by a DHA-licensed phlebotomist during a scheduled home visit. All specimens are transported to our ISO-certified laboratory under temperature-controlled cold-chain conditions to ensure genomic integrity.
3. Is genetic counseling included with this test?
Yes, mandatory pre-test and post-test genetic counseling sessions with a board-certified genetic counselor are included. The session covers inheritance patterns, implications for family members, pedigree analysis, and a detailed explanation of your results, fully compliant with UAE data privacy and health information laws.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed under strict confidentiality agreements. Clinical governance and patient consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility ensures complete data sovereignty and the highest standards of patient safety and privacy.
Clinical & Logistical Metadata
| Test Name | TNNI3 Gene (Familial Restrictive Cardiomyopathy Type 1) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood / FTA Card / Extracted DNA |
| Methodology Used | Full-Gene NGS with deep intronic VUS coverage + MLPA backup |
| ICD-10-CM Code | I42.5 |
| LOINC Code | 78920-1 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians